natgillin/translations-raw huggingface dataset:
In the Week 96 pooled analysis of antiretroviral -naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in the Phase 3 studies GS-US-292-0104 and GS-US-292-0111, the development of one or more primary resistance-associated mutations was observed in HIV-1 isolates from 10 of 866 (1.2%) patients treated with E/C/F/TAF.
V združeni analizi v 96. tednu v študijah faze III GS-US-292-0104 in GS-US-292-0111 pri bolnikih, ki se predhodno niso zdravili s protiretrovirusnimi zdravili in so prejemali elvitegravir/kobicistat/emtricitabin/alafenamidtenofovirat (E/C/F/TAF), so opazili razvoj ene ali več primarnih mutacij pri izolatih HIV-1 pri 10 od 866 (1,2 %) bolnikov, ki so prejemali zdravljenje z zdravilom E/C/F/TAF.
In the week 96 pooled resistance analysis of the Phase III trials (ECHO and THRIVE), 42 out of 86 subjects with virologic failure on rilpivirine showed treatment-emergent resistance to rilpivirine (genotypic analysis).
Po podatkih analize združene rezistence po 96 tednih zdravljenja iz študij faze III (ECHO in THRIVE) se je pri 42 od 86 preiskovancev z virološkim neuspehom zdravljenja z rilpivirinom pokazala zaradi zdravljenja nastala rezistenca na rilpivirin (genotipska analiza).
In the younger age groups (2-6 years and 7-11 years), total clearance was higher compared with that in adolescents, resulting in a lower level of exposure (AUC and Cmax) and elimination half-life.
Pri mlajših starostnih skupinah (2-6 let in 7-11 let) je bil celotni očistek večji kot pri mladostnikih, zato so bile pri njih vrednosti izpostavljenosti zdravilu (AUC in Cmax) nižje, razpolovni čas izločanja pa krajši.
In the zoledronic acid -treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1).
V skupine, zdravljeni z zoledronsko kislino, so v 4. tednu in vsako naslednjo časovno točko v študiji v primerjavi s placebom opazili statistično značilno izboljšanje rezultata bolečine (z uporabo vprašalnika BPI (Brief Pain Inventory) (slika 1).
In the zoledronic acid treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1).
V skupine, zdravljeni z zoledronsko kislino, so v 4. tednu in vsako naslednjo časovno točko v študiji v primerjavi s placebom opazili statistično značilno izboljšanje rezultata bolečine (z uporabo vprašalnika BPI (Brief Pain Inventory) (slika 1).
In the zoledronic acid-treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1).
V skupini, zdravljeni z zoledronsko kislino, so v primerjavi s placebom ugotovili statistično značilno izboljšanje ocene bolečin (z uporabo lestvice BPI – Brief Pain Inventory) po 4 tednih in na vseh nadaljnjih časovnih točkah med študijo (Slika 1).
In the “crimped area” on either side of the ampoule tail
"Stisnjen del" na obeh straneh spodnjega dela ampule
In the “Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0,70 % vs.
V preizkušanju PRoFESS (Prevention Regimen For Effectively avoiding Second Strokes) se je pri bolnikih, starih 50 let in več, ki so pred kratkim doživeli možgansko kap, med jemanjem telmisartana povečala pojavnost sepse, in sicer pri 0,70 % v primerjavi z 0,49 % pri zdravljenih s placebom (RR 1,43; 95-odstotni interval zaupanja od 1,00 do 2,06).
In the “Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs.
V raziskavi “Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) z bolniki, starimi 50 let in več, ki so nedavno preboleli kap, so opazili povečano incidenco sepse pri bolnikih s telmisartanom v primerjavi z bolniki s placebom (0,70 % v primerjavi z 0,49 % [RR 1,43 (95 % interval zaupanja 1,00 – 2,06)].
In theAPC trial, there was a dose-related increase in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (adjudicated) with celecoxib compared to placebo over 3 years of treatment.
V preskušanju APC so med 3-letnim zdravljenjem pri celekoksibu v primerjavi s placebom ugotovili z odmerkom povezan porast sestavljenega opazovanega dogodka srčnožilne smrti, miokardnega infarkta ali možganske kapi (presojeno).
In these 52 week duration studies, patients received treatment for 12 weeks, followed by a 40 week non-treatment phase.
V teh 52-tedenskih študijah so bolniki 12 tednov dobivali zdravilo, sledila pa je 40-tedenska faza brez njega.
In these cases it is therefore recommended that the Zonegran total dose should be rounded up or down to the nearest available dose that can be achieved with commercially available tablet strengths of Zonegran (25 mg, 50 mg, 100 mg and 300 mg).
Zato v teh primerih priporočajo, naj se celotni odmerek zdravila Zonegran zaokroži navzgor ali navzdol do najbližjega razpoložljivega odmerka, ki ga je možno doseči z jakostmi tablet zdravila Zonegran, ki so komercialno na voljo (25 mg, 50 mg, 100 mg in 300 mg).
In these cases Oprymea may affect your ability to drive and operate machinery.
V teh primerih lahko zdravilo Oprymea zmanjša vašo sposobnost za vožnjo ali upravljanje strojev.
In these cases, CK levels should be measured.
V teh primerih je treba izmeriti vrednosti kreatin- fosfokinaze.
In these cases, epoetin alfa is used to replace the missing hormone or to increase red blood cell counts.
V teh primerih se za nadomeščanje manjkajočega hormona ali povečanje števila rdečih krvnih celic uporablja epoetin alfa.
In these cases, if clinically appropriate, higher cut-off levels of platelet count for dose reduction (200 x 109/l) and treatment interruption (400 x 109/l) may be considered according to medical judgement.
V takšnih primerih, če je klinično primerno, se lahko v skladu z zdravniško presojo upošteva višjo mejno raven števila trombocitov za zmanjšanje odmerka (200 x 109/l) in prekinitev zdravljenja (400 x 109/l).
In these cases, it is also recommended to check renal function before initiating treatment with metformin.
V tovrstnih primerih je priporočljivo preveriti tudi delovanje ledvic pred pričetkom zdravljenja z metforminom.
In these cases, Perjeta is used together with trastuzumab and docetaxel (other cancer medicines).
V navedenih primerih se zdravilo Perjeta uporablja skupaj s trastuzumabom in docetakselom (drugima zdraviloma za zdravljenje raka).
In these cases, Perjeta is used with trastuzumab and chemotherapy.
V navedenih primerih se zdravilo Perjeta uporablja v kombinaciji s trastuzumabom in kemoterapijo.
In these cases, the dose of ciclosporin should be gradually reduced to zero over four to eight weeks, and the dose of Rapamune increased to obtain blood levels of sirolimus of about 12 to 20 ng/ml.
V teh primerih je treba odmerek ciklosporina v štirih do osmih tednih postopno zmanjšati na nič, odmerek zdravila Rapamune pa povečati do tolikšne mere, da je raven sirolimusa v krvi približno 12 do 20 ng/ml.
In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment.
V teh primerih bolniki večinoma niso imeli niti simptomov niti kliničnih posledic, izvidi jetrnih testov pa so se ponovno normalizirali po prekinitvi zdravljenja.
In these cases, treatment should be discontinued (see section 4.3).
V takem primeru je treba zdravljenje prekiniti (glejte poglavje 4.3).
In these categories of animals the vaccine should be used only according to the benefit-risk assessment by the responsible veterinarian and/or the national Competent Authorities, depending on the current vaccination policies against bluetongue virus.
Pri teh kategorijah živali lahko cepivo uporabimo le na podlagi ocene razmerja med koristjo in tveganjem, ki jo pripravita pristojni veterinar in/ali nacionalni pristojni organ, odvisno od veljavnega programa cepljenja proti virusu bolezni modrikastega jezika.
In these children, the use of Diacomit will be done under the close supervision of the doctor.
Uporaba stiripentola pri teh otrocih poteka pod skrbnim zdravnikovim nadzorom.
In these clinical studies, the animal owners gave Zubrin to their dogs, once daily at a dose of 10 mg per kg dog’s bodyweight with or without food.
V teh kliničnih raziskavah so lastniki živali dajali Zubrin psom enkrat dnevno v odmerku 10 mg na kg telesne mase psa z ali brez hrane.
In these clinical studies, the median time to onset of the first occurrence of haemorrhagic events was 94 days in both studies for the combination of trametinib and dabrafenib.
Pri zdravljenju s kombinacijo trametiniba in dabrafeniba je bila v obeh navedenih kliničnih študijah mediana časa do pojava prve krvavitve 94 dni.
In these clinical trials, clinically significant increases (greater than 3 x Upper Limit of Normal) in serum alanine aminotransferase (ALT), along with clinically significant increases (greater than 2 x Upper Limit of Normal) in serum total bilirubin were observed in 3 patients treated with tolvaptan.
V teh kliničnih preskušanjih so pri 3 bolnikih, zdravljenih s tolvaptanom, opazili klinično pomembno povečanje (več kot 3-kratnik zgornje normalne vrednosti) serumske alanin aminotransferaze (ALT), skupaj s klinično pomembnim povečanjem (več kot 2-kratnik zgornje normalne vrednosti) skupnega serumskega bilirubina.
In these extensions clinical studies, no cases of high-grade intraepithelial neoplasia and no cases of genital warts were observed in subjects who received qHPV vaccine in the base study:
V teh podaljšanjih kliničnih študij pri osebah, ki so prejele qHPV cepivo v izhodiščni študiji, niso opazili primerov intraepitelijske neoplazije visoke stopnje in primerov genitalnih bradavic:
In these fertility and developmental toxicity studies performed in the rat, all effects were related to the pharmacological activity of abiraterone.
V teh študijah plodnosti in razvojnih študijah toksičnega delovanja, ki so bile izvedene pri podganah, so vsi učinki povezani s farmakološkim delovanjem abiraterona.
In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4.
Pri slabih metabolizatorjih presnovo esomeprazola verjetno v glavnem katalizira CYP3A4.
In these individuals, an adequate immune response may not be elicited.
Pri teh posameznikih ustrezen imunski odziv morda ne bo dosežen.
In these patient groups, urinary copper levels should be kept a little above the upper limit of normal or in the high normal range (i.e.
Pri teh skupinah bolnikov naj bodo ravni bakra v urinu vzdrževane malo nad zgornjo mejo normalnih vrednosti ali v visokem delu normalnega območja (t.j., 40
In these patients a 13% (95 CI: 5.0, 27.0) confirmed response rate was observed with a median PFS of 3.6 months (95% CI: 2, 4).
Med temi bolniki so opažali 13-odstotno (95-odstotni IZ: 5,0, 27,0) stopnjo potrjenega odziva z medianim trajanjem preživetja brez napredovanja bolezni 3,6 meseca (95-odstotni IZ: 2, 4).
In these patients a 13% (95% CI: 5.0, 27.0) confirmed response rate was observed with a median PFS of 3.6 months (95% CI: 2, 4).
Med temi bolniki so opažali 13-odstotno (95-odstotni IZ: 5,0, 27,0) stopnjo potrjenega odziva z medianim trajanjem preživetja brez napredovanja bolezni 3,6 meseca (95-odstotni IZ: 2, 4).
In these patients an upper limit of 12 g/dl (7.5 mmol/l) should be aimed for, unless severe symptoms (e.g. angina) dictate otherwise.
Pri takšnih bolnikih naj bi bila ciljna zgornja meja 120 g/l ( 7,5 mmol/l), razen če hudi simptomi (npr. angina pektoris) ne narekujejo drugače.
In these patients an upper limit of 12 g/dl (7.5 mmol/l) should be aimed for, unless severe symptoms (e.g. angina) dictate otherwise.
Pri takšnih bolnikih naj bi bila ciljna zgornja meja 120 g/l, razen če hudi simptomi (npr. angina pektoris) ne narekujejo drugače.
In these patients an upper limit of 12 g/dl (7.5 mmol/l) should be aimed for, unless severe symptoms (e.g. angina) dictate otherwise.
Pri takšnih bolnikih naj bi bila ciljna zgornja meja 120g/l (7,5 mmol/l)), razen če hudi simptomi (npr. angina pektoris) ne narekujejo drugače.
In these patients it is recommended that an electrocardiogram (ECG) is recorded before initiation of treatment with Trobalt and in those with a corrected QT interval >440ms at baseline, an ECG should be recorded on reaching the maintenance dose.
Takšnim bolnikom je pred začetkom zdravljenja z zdravilom Trobalt priporočljivo posneti elektrokardiogram (EKG); tistim, ki imajo korigirani interval QT izhodiščno > 440 ms, je treba EKG posneti, ko dosežejo vzdrževalni odmerek.
In these patients requiring cautious dosing, oral formulation should be preferred (see section 5.2).
Pri teh bolnikih mora biti odmerjanje previdno, prednost mora imeti peroralna oblika zdravila (glejte poglavje 5.2).
In these patients Revolade should only be used if clinically indicated and patients should then be closely monitored.
Pri teh bolnikih naj se zdravilo Revolade uporablja le, če obstajajo klinične indikacije, bolnike pa je treba skrbno nadzorovati.
In these patients the rate of clinically relevant infection while on MabThera was 6.01 per 100 patient years compared to 4.97 per 100 patient years following treatment with the biologic DMARD.
Delež klinično pomembnih okužb pri teh bolnikih je bil 6,01 na 100 bolnik-let, ko so se zdravili z zdravilom MabThera, v primerjavi s 4,97 na 100 bolnik-let po tem, ko so prejeli nadaljnje zdravljenje z biološkim DMARD.
In these patients, ACR 20/50/70 responses at Week 52 were of 57%, 25%, and 11% respectively.
Pri teh bolnikih so bili odzivi po ACR 20/50/70 po 52 tednih 57 %, 25 % oziroma 11 %.
In these patients, blood clots do not form properly, resulting in longer bleeding time and poor wound healing.
Pri teh bolnikih se krvni strdek ne oblikuje pravilno, zaradi česar je čas krvavitve daljši in se rana slabo celi.
In these patients, Bortezomib Accord is used in combination with melphalan and prednisone; previously untreated adults who are going to receive high-dose chemotherapy followed by blood stem-cell transplantation.
Pri teh bolnikih se zdravilo Bortezomib Accord uporablja v kombinaciji z melfalanom in prednizonom; predhodno nezdravljenih bolnikih, ki bodo prejeli kemoterapijo z velikimi odmerki, čemur bo sledila presaditev krvotvornih matičnih celic.
In these patients, Bortezomib Hospira is used in combination with melphalan and prednisone; previously untreated adults who are going to receive high-dose chemotherapy followed by blood stem-cell transplantation.
Pri teh bolnikih se zdravilo Bortezomib Hospira uporablja v kombinaciji z melfalanom in prednizonom; predhodno nezdravljenih bolnikih, ki bodo prejeli kemoterapijo z velikimi odmerki, čemur bo sledila presaditev krvotvornih matičnih celic.
In these patients, Bortezomib Sun is used in combination with melphalan and prednisone; previously untreated adults who are going to receive high-dose chemotherapy followed by blood stem-cell transplantation.
Pri teh bolnikih se zdravilo Bortezomib Sun uporablja v kombinaciji z melfalanom in prednizonom; predhodno nezdravljenih odraslih, ki bodo prejeli kemoterapijo z velikimi odmerki, čemur bo sledila presaditev krvotvornih matičnih celic.
In these patients, Cimzia is given in combination with methotrexate.
Pri teh bolnikih se zdravilo Cimzia daje v kombinaciji z metotreksatom;
In these patients, clinical remission was achieved in 23% of patients at Week 28 and 32% of patients at Week 52.
Klinična remisija v 28. tednu je bila dosežena pri 23 % takšnih bolnikov, v 52. tednu pa pri 32 % bolnikov.
In these patients, clinical remission was achieved in 25% of patients at Week 28 and Week 52.
Klinična remisija v 28. tednu in 52. tednu je bila dosežena pri 25 % teh bolnikov.
In these patients, enoxaparin sodium should be prescribed for at least 2 days and the treatment should be continued to achieve its objective.
Zdravljenje z natrijevim enoksaparinatom je treba tem bolnikom predpisati za vsaj 2 dni in ga nadaljevati, dokler ni dosežen namen zdravljenja.
In these patients, non-renal events were generally comparable between patients with renal impairment and those without renal impairment, except a >10% higher incidence in dehydration (all grades) was noted (see section 4.4).
Pri teh bolnikih so bili neledvični učinki na splošno primerljivi med bolniki z okvaro ledvic in tistimi brez nje; izjema je bila dehidracija (vseh stopenj), katere incidenca je bila > 10 % večja (glejte poglavje 4.4).
In these patients, opioids may decrease respiratory drive and increase airway resistance.
Pri teh bolnikih opioidi lahko zmanjšajo težnjo po dihanju in povečajo upor dihalnih poti.
In these patients, ramucirumab should only be used if the potential benefits of treatment are judged to outweigh the potential risk of progressive hepatic failure.
Pri teh bolnikih lahko zdravilo uporabite le, če presodite, da možne koristi zdravljenja odtehtajo možna tveganja progresivne jetrne odpovedi.
In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.
Pri bolnikih, ki metotreksata ne prenašajo ali zanje nadaljnje zdravljenje z metotreksatom ni primerno, se lahko zdravilo RoActemra uporabi v monoterapiji.
In these patients, the addition of ribavirin to Viraferon increased by as much as 10-fold the efficacy of Viraferon used alone in the treatment of chronic hepatitis C (48.6 % vs.
Pri teh bolnikih je dodatek ribavirina zdravilu Viraferon povečal učinkovitost samega zdravila Viraferon v monoterapiji kroničnega hepatitisa C za kar 10-krat (48,6 % v primerjavi s 4,7 %).
In these patients, the dose titration should be performed with caution.
Pri teh bolnikih je pri titraciji odmerka potrebna previdnost.
In these patients, the majority of lymphocyte counts remained <0.5 x 109/L with continued therapy.
Pri teh bolnikih je število limfocitov pri nadaljnjem zdravljenju večinoma ostalo < 0,5 x 109/l.
In these patients, the maximum toxicity of Grade 1 or 2 was experienced in 125 (56%) patients, Grade 3 in 76 patients (34%), and Grade 4 in 23 (10%) patients.
Pri teh bolnikih je do maksimalne toksičnosti stopnje 1 ali 2 prišlo pri 125 (56 %) bolnikih, stopnje 3 pri 76 (34 %) bolnikih in stopnje 4 pri 23 (10 %) bolnikih.
In these patients, the mean change in timed function tests from baseline to Week 48 was better in the ataluren 10-, 10-, 20-mg/kg arm than placebo in time to run/walk 10 meters (better by 3.5 seconds), time to climb 4 stairs (better by 6.4 seconds), and time to descend 4 stairs (better by 5.0 seconds).
Povprečna sprememba v časovno merjenih funkcijskih testih od izhodišča do 48. tedna je bila pri teh bolnikih boljša v skupini z atalurenom v odmerkih 10, 10 in 20 mg/kg kot v skupini s placebom, tako pri času teka/hoje na 10 metrov (boljša za 3,5 sekunde), času vzpenjanja po 4 stopnicah (boljša za 6,4 sekunde) kot tudi času spuščanja po 4 stopnicah (boljša za 5,0 sekund).
In these patients, Velcade is used in combination with melphalan and prednisone; previously untreated patients who are going to receive high-dose chemotherapy followed by a blood stem-cell transplant.
Pri teh bolnikih se zdravilo Velcade uporablja v kombinaciji z melfalanom in prednizonom; predhodno nezdravljenih bolnikih, ki bodo prejeli kemoterapijo v visokih odmerkih, čemur bo sledila presaditev krvnih matičnih celic.
In these patients, visual acuity was reduced in 6.5% of patients treated with pregabalin, and 4.8% of placebo-treated patients.
Med temi bolniki so zmanjšanje ostrine vida ugotovili pri 6,5% bolnikov, ki so dobivali pregabalin, in pri 4,8% tistih, ki so dobivali placebo.
In these patients, who generally have poor outcomes and lack suitable treatments, Adcetris could lead to a cure or could enable them to undergo potentially curative treatments.
Pri teh bolnikih, pri katerih je prognoza večinoma neugodna in za katere ni primernih zdravljenj, lahko zdravilo Adcetris vodi do ozdravitve ali jim lahko omogoči potencialno kurativno zdravljenje.
In these pharmacokinetic trials, the exposure of atazanavir 300 mg with cobicistat 150 mg was consistent with that observed when boosted with ritonavir 100 mg.
V teh farmakokinetičnih preskušanjih je bila izpostavljenost atazanavirju pri uporabi atazanavirja v odmerku 300 mg skupaj s kobicistatom v odmerku 150 mg konsistentna z izpostavljenostjo pri okrepitvi z ritonavirjem v odmerku 100 mg.
In these pooled trials, the median exposure for patients in the INTELENCE arm was 52.3 weeks.
V teh združenih preskušanjih je znašala mediana vrednost stopnje izpostavljenosti zdravilu pri bolnikih iz kraka študije z zdravilom INTELENCE 52,3 tedne.
In these reports the MAH is requested to specifically assess cases for whom there is a loss of efficacy (patients reported to have discontinued Ilaris for lack-of-therapeutic response) to determine whether this is due to changes over time in PK/PD or antibody development (where data is available) or in whom a dose adjustment has led to improved therapeutic response (patients with a dose up titration without discontinuation for lack-of- therapeutic response).
V teh poročilih mora imetnik dovoljenja za promet z zdravilom navesti specifične ocene primerov, v katerih je šlo za izgubo učinkovitosti zdravila (bolniki, ki so prekinili jemanje zdravila Ilaris zaradi odsotnosti oziroma zmanjšanja terapevtskega odziva), da bi se ugotovilo, ali je do tega prišlo zaradi sprememb farmakokinetičnih/farmakodinamičnih lastnosti zdravila med terapijo ali zaradi razvoja protiteles (če so na voljo ustrezni podatki),oziroma primerov, v katerih je sprememba odmerka povzročila izboljšanje terapevtskega odziva (pri bolnikih z zvišanimi odmerki, ki niso prekinili terapije zaradi odsotnosti oziroma zmanjšanja terapevtskega odziva).
In these situations an individual benefit-risk assessment is mandatory and patients should be monitored for occurrence of QT prolongation.
V tem primeru je obvezna individualna ocena razmerja med koristjo in tveganjem, bolnike pa je treba spremljati glede pojava podaljšanja intervala QT.
In these situations you should seek immediate medical care in order to receive treatment with injections of hydrocortisone and extra fluid administration.
V teh primerih nemudoma poiščite zdravniško pomoč, da prejmete zdravljenje z injekcijami hidrokortizona in dodatno tekočino.
In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale.
Pri teh boleznih je pljučni vaskularni upor (PVR – »pulmonary vascular resistance«) visok, kar povzroča hipoksemijo kot posledico obvoda krvi z desne na levo stran skozi ductus arteriosus in foramen ovale bolnika.
In these studies Darzalex was not compared with any other treatment.
V teh študijah zdravila Darzalex niso primerjali z nobenim drugim zdravilom.
In these studies serious bleeding events included any intracranial haemorrhage, any life-threatening or fatal bleed, any bleeding event requiring the administration of  3 units of packed red blood cells per day for 2 consecutive days, or any bleeding event assessed as serious by the investigator.
V teh študijah so resne krvavitve vključevale katerokoli intrakranialno krvavitev, kakršnokoli smrtno nevarno ali usodno krvavitev, kakršnokoli krvavitev, ki je zahtevala dajanje  3 enot koncentriranih eritrocitov na dan 2 zaporedna dneva, ali kakršnokoli krvavitev, ki jo je kot resno ocenil preiskovalec.
In these studies the ability of Thyrogen to stimulate left-over thyroid tissue was compared with the patients’ own TSH.
V teh dveh študijah so primerjali zmožnost zdravila Thyrogen za stimulacijo preostalega ščitničnega tkiva z bolnikom lastnim hormonom TSH.